Intracameral injection of bevacizumab (Avastin) to treat anterior chamber neovascular membrane in a painful blind eye

Indian J Ophthalmol. 2007 Nov-Dec;55(6):460-2. doi: 10.4103/0301-4738.36484.

Abstract

Intracameral injection of bevacizumab (Avastin) helped in the successful regression of an anterior chamber neovascular membrane in a painful blind eye. The effect was persistent even after six months of follow-up. This is the first report on intracameral administration of bevacizumab with six months of follow-up.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage*
  • Anterior Chamber / blood supply*
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Blindness / complications*
  • Female
  • Follow-Up Studies
  • Humans
  • Injections
  • Neovascularization, Pathologic / complications
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / pathology
  • Pain / complications*
  • Time Factors
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab